20 December 2018
Download the full announcement here
EKF Diagnostics Holdings plc ("EKF" or the "Company")
Update regarding planned change of nominated adviser
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, announces that, further to the announcement on 1 November regarding its planned appointment of a new nominated adviser following the admission of Renalytix AI PLC (“RenalytixAI”) to trading on AIM, the boards of EKF and RenalytixAI have now agreed a different resolution to the requirement for one of the two companies to appoint a new nominated adviser.
The proposed change remains driven by the regulatory requirement for an AIM issuer to retain an independent nominated adviser. Following EKF’s decision to invest in the placing which took place alongside the admission to trading on AIM of RenalytixAI, it was no longer possible for N+1 Singer to continue to act as an independent nominated adviser to both companies.
By mutual agreement of all parties, N+1 Singer will now remain as current nominated adviser and broker to EKF.
To preserve the independence of its nominated adviser, RenalytixAI will appoint a new nominated adviser and joint broker, with US distribution capability which aligns with the company’s US-based business operations and the initial target market for its products.
N+1 Singer will continue to act as nominated adviser and broker to RenalytixAI in the interim, and as joint broker following the new appointment by RenalytixAI. A further announcement will be made in the New Year by RenalytixAI with regard to the new appointment.
EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Julian Baines, CEO Richard Evans, FD & COO
|Tel: 029 2071 0570
N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)
|Tel: 020 7496 3000
Walbrook PR Limited
Paul McManus / Lianne Cawthorne
|Tel: 020 7933 8780 or email@example.com
Mob: 07980 541 893 /
07584 391 303